Mobile

An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-000357-35

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the preliminary efficacy of nilotinib in pretreated patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as stable disease (SD), partial response (PR) or complete response (CR) during the first 4 months according to RECIST criteria.

Critère d'inclusion

  • gastrointestinal stromal tumors

Liens